Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Treasury Shares: 2015-2024

Historic Treasury Shares for Spyre Therapeutics (SYRE) over the last 1 years, with Dec 2024 value amounting to $115,398.

  • Spyre Therapeutics' Treasury Shares fell 25.00% to $115,398 in Q4 2024 from the same period last year, while for Dec 2024 it was $115,398, marking a year-over-year decrease of 25.00%. This contributed to the annual value of $115,398 for FY2024, which is 25.00% down from last year.
  • Spyre Therapeutics' Treasury Shares amounted to $115,398 in Q4 2024, which was down 25.00% from $153,865 recorded in Q4 2023.
  • Over the past 5 years, Spyre Therapeutics' Treasury Shares peaked at $228,200 during Q4 2020, and registered a low of $5,660 during Q4 2022.
  • Its 3-year average for Treasury Shares is $132,737, with a median of $151,932 in 2022.
  • As far as peak fluctuations go, Spyre Therapeutics' Treasury Shares crashed by 97.02% in 2022, and later surged by 2,618.46% in 2023.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Treasury Shares stood at $228,200 in 2020, then decreased by 16.74% to $190,000 in 2021, then slumped by 97.02% to $5,660 in 2022, then spiked by 2,618.46% to $153,865 in 2023, then dropped by 25.00% to $115,398 in 2024.
  • Its Treasury Shares stands at $115,398 for Q4 2024, versus $153,865 for Q4 2023 and $5,660 for Q4 2022.